896. Cost-Avoidance Associated with Active Stewardship of Remdesivir

Abstract Background The COVID pandemic shifted antimicrobial stewardship resources at community hospitals. One reason for this shift was new treatments, the first of which remdesivir, received initial emergency use authorization (EUA) treatment COVID-19 in May 2020. UNC Health Southeastern (UNC SEH) pharmacy director stewarded remdesivir by reviewing patients to ensure they met and guideline-based appropriateness criteria. infectious diseases physician resolved any disputes regarding patient candidacy remdesivir. goal optimize care; however, workflow presented an unrecognized opportunity stewards reduce costs. Methods percentage admissions receiving SEH calendar years 2020 2021 benchmarked against 32 hospitals Duke Antimicrobial Stewardship Outreach Network (DASON) (Figure 1). purchasing data were used calculate expenditures 2021. Next, anticipated cost if hospital had prescribed same as DASON mean calculated. difference calculated determine avoidance achieved having below average (Table Results At SEH, 28.1% annual $693,680. In 2021, 47.45% drug $1,248,000. % 44.08% 60.07% A total $726,407 based on hospital’s below-benchmark Conclusion significant cost-savings due active stewardship. team created a patient-centered model that focused using drugs right organization realized while ensuring therapy accordance with EUAs published guidelines. Disclosures All Authors: No reported disclosures.